Jury Says BGI Owes Illumina $8M For Infringing DNA Patents

By Hannah Albarazi · November 30, 2021, 11:16 PM EST

A California federal jury determined Tuesday that four out of five of Illumina's patents behind its next-generation genome-sequencing technology were valid, finding that Illumina's Chinese rival BGI Genomics and its subsidiaries willfully...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Illumina, Inc. et al v. BGI Genomics Co., Ltd et al

Case Number

3:19-cv-03770

Court

California Northern

Nature of Suit

Patent

Date Filed

June 27, 2019